Literature DB >> 2849512

Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype.

J Woolford1, A McAuliffe, L R Rohrschneider.   

Abstract

The v-fms oncogene is capable of producing tumors in vivo and transforming cells in culture; in contrast, the c-fms proto-oncogene is nontransforming. In this report we present the complete nucleotide sequence of a feline c-fms cDNA, the progenitor of the v-fms oncogene. Comparison of this sequence with that of v-fms shows that the proteins encoded by these two genes differ by nine amino acid substitutions and the replacement of 50 C-terminal amino acids present in c-fms by 11 unrelated residues in v-fms. Using chimeric fms genes and site-directed mutagenesis, we have determined that the C-terminal modification present in v-fms is sufficient to generate a partially transforming phenotype, but that mutations at amino acid positions 301 and 374 are required (in addition to the C-terminal modification) to generate a fully transforming fms gene.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849512     DOI: 10.1016/0092-8674(88)90242-5

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  46 in total

1.  Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor).

Authors:  A Mondino; S Giordano; P M Comoglio
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

2.  Epidermal growth factor receptor cytoplasmic domain mutations trigger ligand-independent transformation.

Authors:  S Massoglia; A Gray; T J Dull; S Munemitsu; H J Kun; J Schlessinger; A Ullrich
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

3.  FMS mutations in myelodysplastic, leukemic, and normal subjects.

Authors:  S A Ridge; M Worwood; D Oscier; A Jacobs; R A Padua
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

4.  CSF-1R up-regulation is associated with response to pharmacotherapy targeting tyrosine kinase activity in AML cell lines.

Authors:  Michael Kogan; Tracy Fischer-Smith; Rafal Kaminsky; Gabrielle Lehmicke; Jay Rappaport
Journal:  Anticancer Res       Date:  2012-03       Impact factor: 2.480

5.  Mouse NIH 3T3 cells expressing human colony-stimulating factor 1 (CSF-1) receptors overgrow in serum-free medium containing human CSF-1 as their only growth factor.

Authors:  M F Roussel; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

6.  Early pre-B-cell transformation induced by the v-fms oncogene in long-term mouse bone marrow cultures.

Authors:  G V Borzillo; C J Sherr
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

7.  A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype.

Authors:  C Collesi; M M Santoro; G Gaudino; P M Comoglio
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

8.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

Authors:  T Furitsu; T Tsujimura; T Tono; H Ikeda; H Kitayama; U Koshimizu; H Sugahara; J H Butterfield; L K Ashman; Y Kanayama
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Tyrosine 706 and 807 phosphorylation site mutants in the murine colony-stimulating factor-1 receptor are unaffected in their ability to bind or phosphorylate phosphatidylinositol-3 kinase but show differential defects in their ability to induce early response gene transcription.

Authors:  P van der Geer; T Hunter
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

10.  Identification of the ligand-binding regions in the macrophage colony-stimulating factor receptor extracellular domain.

Authors:  Z E Wang; G M Myles; C S Brandt; M N Lioubin; L Rohrschneider
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.